Pdl Biopharma Inc (PDLI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2003 | 12-2002 | 09-2002 | 06-2002 | 03-2002 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 4,069 | -14,554 | -6,670 | 1,322 | 1,881 |
| Depreciation Amortization | 1,603 | 6,162 | 4,511 | 2,899 | 1,412 |
| Accounts payable and accrued liabilities | 583 | 379 | -317 | -367 | 846 |
| Other Working Capital | 781 | 1,955 | 2,308 | 1,664 | -2,419 |
| Other Operating Activity | -433 | 987 | 317 | 367 | -846 |
| Operating Cash Flow | $6,603 | $-5,071 | $149 | $5,885 | $874 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 79,916 | 203,546 | 140,046 | 100,046 | 120,046 |
| PPE Investments | -17,542 | -34,786 | -24,003 | -15,524 | -7,874 |
| Investing Cash Flow | $62,374 | $168,760 | $116,043 | $84,522 | $112,172 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -115 | -432 | -322 | -212 | -107 |
| Common Stock Issued | 27 | 4,205 | 3,301 | 2,323 | 1,055 |
| Financing Cash Flow | $-88 | $3,773 | $2,979 | $2,111 | $948 |
| Beginning Cash Position | 287,730 | 120,268 | 120,268 | 120,268 | 120,268 |
| End Cash Position | 356,619 | 287,730 | 239,439 | 212,786 | 234,262 |
| Net Cash Flow | $68,889 | $167,462 | $119,171 | $92,518 | $113,994 |
| Free Cash Flow | |||||
| Operating Cash Flow | 6,603 | -5,071 | 149 | 5,885 | 874 |
| Capital Expenditure | -17,542 | -34,786 | -24,003 | -15,524 | -7,874 |
| Free Cash Flow | -10,939 | -39,857 | -23,854 | -9,639 | -7,000 |